Regional administration of recombinant tumour necrosis factor-a in cancer, with special reference to melanoma

BioDrugs

Volumn 9, Issue 3, 1998, Pages 211-218

  Lejeune, Ferdy ^a   Lienard, Danielle ^b   Eggermont, Alexander ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; INTERLEUKIN 6; MELPHALAN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIMB PERFUSION; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA;

EID: 0031925043     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199809030-00004     Document Type: Article

References (42)

1. Cm-swell EA. OKI U. Kassel KL. et al. An endoloxin-indueed serum factor that causes necrosis of tumours. Proc Natl Acad Sci USA 1975: 72: 3666-70
2. Aggarwal BB, Kohr WJ. Mass PE. et al. Human tumour necrosis factor: production, purification and characterisation. J Biol Chem 19X5:260: 2345-54
3. Fransen L. Muller R. Marmenout A. et al. Molecular cloning of mouse tumour necrosis factor cDNA and its eukaryotic expression. Nucleic Acids Res 1985; 13: 4417-29
4. Pennica D. Hayflick JS. Bringman TS. et al. Cloning and expression in E. coli of the cDNA for murine tumour necrosis factor. Proc Natl Acad Sci USA 1985: 82: 6060-4
5. Old IJ. Tumor necrosis factor (TNF). Science 1985; 230: 630-2
6. Spriggs DR. Sherman ML. Michie H. et al. Recombinant human tumor necrosis factor administered as a 24h intravenous infusion: a phase I and pharmacologie study. J Natl Cancer Inst 1988: 80: 1039-44
7. Feinherg B. Kurzock T, Talpaz M. et al. A phase I trial of intravenously administered recombinant tumour necrosis factor alpha in cancer patients. J Clin Oncol 188 6: 1328-34
8. Liénard D. Ewalenko P. Delmotte J-.I. et al. High-dose recomhinant tumour necrosis factor alpha in combination with interleron gamma and melphalan in isolation perfusion of the limbs tor melanoma and sarcoma. J Clin Oncol 1992; Id: 52-60
9. Liénard D. Lcjeune FJ. Ewalenko P. In transit métastases of malignant melanoma treated by high dose rTNFcx in combination witth interferon-gamma and melphalan in isolation per fusion. World J Stirg 1992; 16: 234-40
10. Liénard D, Eggermont AMM, Schraffordl Koops H. et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNFct). interferon-gamma lIFNy) and melphalan for melanoma stage III: results of a multi-centre pilot study. Melanoma Res 1994: 4: 21 6
11. Lejeune FJ. High dose recombinanl tumour necrosis factor (rTNFa) administered by isolation perfusion for advanced tumours of the limbs: a model forbiochemotherapy ol cancer. EnrJ Cancer 1995: 3IA: 1009-16
12. Fiers W. Brouckaert P. GuiseJ. Y. Recoinbinant Interferon gamma and its syuergism with tumour necrosis factor in the human and mouse systems. In: Schellkens H. Stewart WE. editors. The biology of the Interferon system. Amsterdam: EKevier Science. J986: 241-8
13. Bulkwill FR. Lee A. Aldam G. et al. Human tumor xenografts treated with recomhinant human tumor necrosis factor alone or in combination with interferons. Cancer Res 1986: 46: 3990-3
14. Haranaka K. Satomi N. Sakurai A. et al. Antitumour effects of tumour necrosis factor: cytotoxic or necrotiling activity and its mechanism. Ciba Found Symp 1987: 131: 140-53
15. Balkwill F. Lee A. Aklom G. et al. Human tumour xenografts treated with human TNF alone or in combination with interleron. Cancer Res 1986: 46: 3990-3
16. Fiers W. Brouckaert P. Guisel Y. Recomhinant Interferon gamma and its synergism with tumour necrosis factor in the human and mouse systems. In: Schellekens H. Stewart WE. editors. The biology of the interleron system. Amsterdam: Flsevier Science. 1986: 241-8
17. Chapman PB. Lester TJ, Casper ES. el al. Clinical pharmacol ogy of recombinant human tumour necrosis factor in patients with adl anced cancer. J Clin Oncol 1987: 5: 1942-5 I
18. Sherman ML. Spriggs DR. Arthur KA. et al. Recomhinant hu man tumour necrosis factor administered as a five day continuous infusion in cancer patients: phase I loxicily and effects on lipid metabolism. J Clin Oncol 1988: 6: 344-50
19. Monson JR. Ramsey PS. Donohue JH. Taurolidine inhibits tumour necrosis faclor (TNF) toxicity: new evidence of TNF andendotoxin synergy. Fur J Surg Oncol 1993: 19: 226-31
20. Bone RC. Balk RA. Cerra FB. el al. Definitions lor sepsis and organ failure and guidelines tbi the use of innovative therapies in sepsis. Chest 1992: 101: 1644-55
21. Creech O. R> an R. Kreinemz FT Treatment of malignant mclanoma by isolation perfusion technique. JAMA 1959: 169: 339-43
22. Old L.J. Introduction. In: Bonavida B. Granger G. editors. Tumor necrosis factor: structure, mechanism til action, role in disease and therapy. Basel: Karger. 1990: 1-30
23. Gerain J. Lieuard D. Fwalenko P. et al. High serum lelels of TNF-alpha after its administration for isolation perfusion ol the limb. Cuokme 1992: 4: 585-91
24. Posner M. Liénard D. Lejeune FJ. et al. Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor (TNF) alone tor metastatic in-transit melanoma. Proc Am Soc Clin Oncol 1994: 13: 396
25. Sohmura Y. Antitumour effect of recomhinant human tumour necrosis faclor alpha and its augmentation in vitro and in vivo. In: Bonavida B. Clifford GE. Kirchner H. et al., editors. Tu-
26. mour necrosis factorlcachectin and related cytokines. Basel: Karger. 1988: 189-95
27. Manusama ER. Nooijen PTGA, Stavas J, et al. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br JSurg 1996:83:551-5
28. Aggarwal BB, Eessalu TE, Hass PE. Characterisation of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature 1985; 318: 665-7
29. Alexander Jr HR. Fraker DL, Bartlett DL. Isolated limb perfusion for malignant melanoma. Semin Surg Oncol 1996; 12: 416-28
30. Gaynor JJ, Tan CC, Casper ES, et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 10: 1317-27
31. Brennan ME, Shiu MH, Collin C, et al. Extremity soft tisue sarcomas. Cancer Treat Symp 1985; 3: 71-81
32. Stotier AT, A'Hearn RP, Fisher C, et al. The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer 1990; 65: 1119-29
33. Gustafson P, Röser B, Rydholm A. Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer 1991:67: 2083-6
34. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha for locally advanced extremity soft tissue sarcomas. Cancer Treat Res 1997; 91: 189-203
35. Eggermont AMM, Schraffordt Koops H, Liénard D, et al. Isolated limb perfusion with high-dose tumour necrosis factoralpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14: 2653-65
36. Renard N. Liénard D, Lespagnard L, et al. Early endothelium activation and polymorphonuelear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high dose tumour necrosis factor alpha. Int J Cancer 1994; 57: 656-63
37. Renard N, Nooijen, Schalkwijk L, et al. VWF release and platelet aggregation in human melanoma after perfusion with TNFot. J Pathol 1995; 176: 279-87
38. Riiegg C, Yilmaz A, Bieler G, et al. Evidence for the involvement of endothelial cell inlegrin ocV3 in the disruption of the tumour vasculature induced by TNF and IFNy. Submitted
39. Eggiman P, Chiolero R, Chassot PC, et al. Systemic and hemodynamic effects of recombinant tumour necrosis factor alpha in isolation perfusion of the limbs. Chest 1995: 107: 1074-82
40. Gérain J, Baumgartner M, Liénard D, et al. Systemic release of soluble TNF receptors after high dose TNF in isolated limb perfusion. Cytokine 1997 Dec; 9 (12): 1034-42
41. Schenk S, Liénard D, Gérain J, el al. Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high dose tumour necrosis factor (TNF), Interferon gamma (IFNy) and melphalan for regionally advanced tumours. Int J Cancer 1995:63:665-72
42. Romero P, De Souza S, Rimoldi D, et al. HLA-A2 restricted CTL responses to melanocyte differentiation antigens in melanoma patients subjected to high-dose TNFa administered by isolated limb perfusion. Melanoma Res 1995: 5: 30-1